西妥昔单抗+DF方案化疗治疗中晚期鼻咽癌患者的临床研究(1)
【摘要】 目的：研究西妥昔单抗+DF方案化疗治疗中晚期鼻咽癌患者的临床效果。方法：选取2017年4月-2019年1月本院收治的54例中晚期鼻咽癌患者。简单随机化分为观察组和对照组，各27例。对照组予以调强放疗与DF方案化疗，观察组在对照组基础上加用西妥昔单抗，比较两组缓解率、血清相关指标水平(MMP-2、MMP-14、ⅣC、PCⅢ、LN、MIP-3α、EGFR)、毒副反应。结果：观察组缓解率92.59%，高于对照组的70.37%(字2=4.418，P=0.036);治疗后，观察组MMP-2、MMP-14、ⅣC、PCⅢ、LN、MIP-3α、EGFR均低于对照组(P<0.05);两组骨髓抑制、皮炎、口腔黏膜反应、消化道反应、肝肾功能损伤发生率比较，差异均无统计学意义(P>0.05)。结论：西妥昔单抗+DF方案化疗治疗中晚期鼻咽癌，可提高肿瘤缓解率，抑制肿瘤转移，具有一定安全性。
【关键词】 西妥昔单抗; DF方案化疗; 中晚期鼻咽癌
Clinical Study of Cetuximab+DF Regimen Chemotherapy for Advanced Nasopharyngeal Carcinoma/XU Qiuping.//Medical Innovation of China，2019，16(27)：0-017
【Abstract】 Objective：To study the clinical effect of Cetuximab+DF regimen chemotherapy in treatment of advanced nasopharyngeal carcinoma.Method：A total of 54 patients with advanced nasopharyngeal carcinoma admitted to our hospital from April 2017 to January 2019 were selected.Simple randomization was used to divide them into observation group and control group，27 cases in each group.The control group received intensity modulated radiotherapy and DF regimen chemotherapy，while observation group received Cetuximab on the basis of control group.The remission rate，serum related indicators(MMP-2，MMP-14，ⅣC，PCⅢ，LN，MIP-3α，EGFR)and toxicity between two groups were compared.Result：The remission rate of observation group was 92.59%，which was higher than 70.37% of control group(字2=4.418，P=0.036).After treatment，the levels of MMP-2，MMP-14，ⅣC，PCⅢ，LN，MIP-3α and EGFR in observation group were lower than those of control group(P<0.05).The incidence of bone marrow depression，dermatitis，oral mucosal reaction，digestive tract reaction and liver and kidney function damage between two groups were compared，the differences were not statistically significant(P>0.05).Conclusion：Cetuximab+DF regimen chemotherapy for advanced nasopharyngeal carcinoma can increase the tumor remission rate and inhibit tumor metastasis，has certain security.
【Key words】 Cetuximab; DF regimen chemotherapy; Advanced nasopharyngeal carcinoma
First-author’s address：Fengcheng People’s Hospital，Fengcheng 331100，China
doi：10.3969/j.issn.1674-4985.2019.27.004
鼻咽癌是一種易发生局部浸润的头颈部恶性肿瘤，近年来随着诊断技术提升，检出率呈递增趋势[1]。放化疗是治疗鼻咽癌重要策略，早期患者实施放化疗即可获得满意效果，但中晚期患者易发生局部复发与转移，需采用综合性治疗手段[2]。根据以往研究，约80%中晚期鼻咽癌患者表皮生长因子受体(EGFR)异常活化或过表达，并与肿瘤细胞侵袭转移、放化疗抵抗、不良预后等息息相关[3]。西妥昔单抗系EGFR单克隆抗体，可抑制细胞分化、生长所依赖的EGFR信号传导通路，促进肿瘤细胞凋亡[4]。本研究选取54例中晚期鼻咽癌患者，从肿瘤缓解率、安全性等多角度，探讨西妥昔单抗+DF方案化疗(顺铂联合5-氟尿嘧啶)的应用价值，现报道如下。, http://www.100md.com(徐秋平)
【关键词】 西妥昔单抗; DF方案化疗; 中晚期鼻咽癌
Clinical Study of Cetuximab+DF Regimen Chemotherapy for Advanced Nasopharyngeal Carcinoma/XU Qiuping.//Medical Innovation of China，2019，16(27)：0-017
【Abstract】 Objective：To study the clinical effect of Cetuximab+DF regimen chemotherapy in treatment of advanced nasopharyngeal carcinoma.Method：A total of 54 patients with advanced nasopharyngeal carcinoma admitted to our hospital from April 2017 to January 2019 were selected.Simple randomization was used to divide them into observation group and control group，27 cases in each group.The control group received intensity modulated radiotherapy and DF regimen chemotherapy，while observation group received Cetuximab on the basis of control group.The remission rate，serum related indicators(MMP-2，MMP-14，ⅣC，PCⅢ，LN，MIP-3α，EGFR)and toxicity between two groups were compared.Result：The remission rate of observation group was 92.59%，which was higher than 70.37% of control group(字2=4.418，P=0.036).After treatment，the levels of MMP-2，MMP-14，ⅣC，PCⅢ，LN，MIP-3α and EGFR in observation group were lower than those of control group(P<0.05).The incidence of bone marrow depression，dermatitis，oral mucosal reaction，digestive tract reaction and liver and kidney function damage between two groups were compared，the differences were not statistically significant(P>0.05).Conclusion：Cetuximab+DF regimen chemotherapy for advanced nasopharyngeal carcinoma can increase the tumor remission rate and inhibit tumor metastasis，has certain security.
【Key words】 Cetuximab; DF regimen chemotherapy; Advanced nasopharyngeal carcinoma
First-author’s address：Fengcheng People’s Hospital，Fengcheng 331100，China
doi：10.3969/j.issn.1674-4985.2019.27.004
鼻咽癌是一種易发生局部浸润的头颈部恶性肿瘤，近年来随着诊断技术提升，检出率呈递增趋势[1]。放化疗是治疗鼻咽癌重要策略，早期患者实施放化疗即可获得满意效果，但中晚期患者易发生局部复发与转移，需采用综合性治疗手段[2]。根据以往研究，约80%中晚期鼻咽癌患者表皮生长因子受体(EGFR)异常活化或过表达，并与肿瘤细胞侵袭转移、放化疗抵抗、不良预后等息息相关[3]。西妥昔单抗系EGFR单克隆抗体，可抑制细胞分化、生长所依赖的EGFR信号传导通路，促进肿瘤细胞凋亡[4]。本研究选取54例中晚期鼻咽癌患者，从肿瘤缓解率、安全性等多角度，探讨西妥昔单抗+DF方案化疗(顺铂联合5-氟尿嘧啶)的应用价值，现报道如下。, http://www.100md.com(徐秋平)